BTK and B-cell chronic lymphocytic leukemia: For previously untreated patients with CLL, the reimbursement criteria implemented by provincial public drug plans across the country have generally limited the use of BTK inhibitors to patients who have high-risk disease features (independent of age) and/or those who are unfit to receive fludarabine (which might include age).